WebSep 21, 2024 · Agenus received $15.0 million at closing and retains the majority (67%) of all future royalties and 90% of all milestones from Incyte and Merck. Agenus also remains eligible to receive up to an ... WebMar 14, 2024 · LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today...
Paris Pearls: Targeting Antibody-Drug Conjugates in Solid Tumors
WebLEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR WebSep 17, 2024 · LEXINGTON, Mass., Sept. 17, 2024 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1, announced today receipt of a cash milestone from Incyte for the initiation of a Phase 1 clinical trial of INCAGN2385, an anti … somersett golf course reno green fees
Incyte and Agenus Amend Collaboration Agreement
WebIn 2024, Agenus and Bristol Myers Squibb entered into a global license agreement for Agenus’ anti-TIGIT bi-specific antibody, BMS-986442 (AGEN1777). WebMar 14, 2024 · Fourth Quarter and Full Year 2024 Financial Results: As of December 31, 2024, we had a cash, cash equivalent and short-term investment balance of $193 million, compared to $218 million and $307 ... WebJan 9, 2015 · Under the terms of the agreements between the parties, Incyte will make upfront payments to Agenus totaling $25 million and invest $35 million by purchasing … somersett golf and country club